Literature DB >> 18710386

Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma.

Akiko Masuda1, Kazuhiro Nakamura, Koji Izutsu, Koji Igarashi, Ryunosuke Ohkawa, Masahiro Jona, Katsumi Higashi, Hiromitsu Yokota, Shinichi Okudaira, Tatsuya Kishimoto, Takuro Watanabe, Yukako Koike, Hitoshi Ikeda, Yasushi Kozai, Mineo Kurokawa, Junken Aoki, Yutaka Yatomi.   

Abstract

Autotaxin (ATX) is a tumour cell motility-stimulating factor originally isolated from melanoma cell supernatants. ATX is identical to lysophospholipase D, which produces a bioactive lipid mediator, lysophosphatidic acid (LPA), from lysophosphatidylcholine. ATX is overexpressed in various malignancies, including Hodgkin lymphoma, and ATX may stimulate tumour progression via LPA production. The present study measured the serum ATX antigen levels in patients with haematological malignancies using a recently developed automated enzyme immunoassay. The serum ATX antigen levels in patients with B-cell neoplasms, especially follicular lymphoma (FL), were higher than those in healthy subjects. Serum ATX antigen levels in FL patients were associated with tumour burden and changed in parallel with the patients' clinical courses. The serum ATX antigen levels were little affected by inflammation, unlike the soluble interleukin-2 receptor and beta2-microglobulin levels. As expected, the plasma LPA levels in FL patients were correlated with the serum ATX antigen levels. Given that leukaemic tumour cells from FL patients expressed ATX, the shedding of ATX from lymphoma cells probably leads to the elevation of serum ATX antigen levels. Our results suggest that the serum ATX antigen level may be a promising and novel marker for FL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18710386     DOI: 10.1111/j.1365-2141.2008.07325.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  43 in total

1.  Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis.

Authors:  Sue-Chin Lee; Yuko Fujiwara; Jianxiong Liu; Junming Yue; Yoshibumi Shimizu; Derek D Norman; Yaohong Wang; Ryoko Tsukahara; Erzsebet Szabo; Renukadevi Patil; Souvik Banerjee; Duane D Miller; Louisa Balazs; Manik C Ghosh; Christopher M Waters; Tamas Oravecz; Gabor J Tigyi
Journal:  Mol Cancer Res       Date:  2014-08-26       Impact factor: 5.852

2.  c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.

Authors:  Stefano Sioletic; Jeffrey Czaplinski; Lan Hu; Jonathan A Fletcher; Christopher D M Fletcher; Andrew J Wagner; Massimo Loda; George D Demetri; Ewa T Sicinska; Eric L Snyder
Journal:  J Pathol       Date:  2014-08-01       Impact factor: 7.996

3.  Knock-down of SOX11 induces autotaxin-dependent increase in proliferation in vitro and more aggressive tumors in vivo.

Authors:  Paolo Conrotto; Ulrika Andréasson; Venera Kuci; Carl A K Borrebaeck; Sara Ek
Journal:  Mol Oncol       Date:  2011-08-22       Impact factor: 6.603

4.  Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.

Authors:  Shih-Chi Su; Xiaoxiao Hu; Patrick A Kenney; Megan M Merrill; Kara N Babaian; Xiu-Ying Zhang; Tapati Maity; Shun-Fa Yang; Xin Lin; Christopher G Wood
Journal:  Clin Cancer Res       Date:  2013-10-11       Impact factor: 12.531

5.  Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.

Authors:  Mandi M Murph; Guowei W Jiang; Molly K Altman; Wei Jia; Duy T Nguyen; Jada M Fambrough; William J Hardman; Ha T Nguyen; Sterling K Tran; Ali A Alshamrani; Damian Madan; Jianxing Zhang; Glenn D Prestwich
Journal:  Bioorg Med Chem       Date:  2015-07-02       Impact factor: 3.641

Review 6.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

Review 7.  Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.

Authors:  Mari Gotoh; Yuko Fujiwara; Junming Yue; Jianxiong Liu; SueChin Lee; James Fells; Ayako Uchiyama; Kimiko Murakami-Murofushi; Stephen Kennel; Jonathan Wall; Renukadevi Patil; Renuka Gupte; Louisa Balazs; Duane D Miller; Gabor J Tigyi
Journal:  Biochem Soc Trans       Date:  2012-02       Impact factor: 5.407

8.  Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid.

Authors:  Renuka Gupte; Anjaih Siddam; Yan Lu; Wei Li; Yuko Fujiwara; Nattapon Panupinthu; Truc-Chi Pham; Daniel L Baker; Abby L Parrill; Mari Gotoh; Kimiko Murakami-Murofushi; Susumu Kobayashi; Gordon B Mills; Gabor Tigyi; Duane D Miller
Journal:  Bioorg Med Chem Lett       Date:  2010-10-08       Impact factor: 2.823

9.  Serum autotaxin is not a useful biomarker for ovarian cancer.

Authors:  Kazuhiro Nakamura; Koji Igarashi; Ryunosuke Ohkawa; Hiromitsu Yokota; Akiko Masuda; Shunsuke Nakagawa; Tetsu Yano; Hitoshi Ikeda; Junken Aoki; Yutaka Yatomi
Journal:  Lipids       Date:  2012-06-15       Impact factor: 1.880

10.  Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.

Authors:  Molly K Altman; Vashisht Gopal; Wei Jia; Shuangxing Yu; Hassan Hall; Gordon B Mills; A Cary McGinnis; Michael G Bartlett; Guowei Jiang; Damian Madan; Glenn D Prestwich; Yong Xu; Michael A Davies; Mandi M Murph
Journal:  Mol Cancer       Date:  2010-06-09       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.